Yeda Research and Develpment & Co. Ltd

Shoshana Eitan

Michal Eisenbach-Schwartz

Michal Schwartz

Michael Schwartz

An enzymatically-producible dimeric IL-2 such as mammalian, more particularly, human dimeric IL-2, having oligodendrocyte cytotoxic activity, is useful as active ingredient of pharmaceutical compositions for inducing and facilitating regeneration of injured nerves of the central nervous system in mammals, including humans.

Enzymatically-produced oligodendrocyte cytotoxic dimeric IL-2 factor

The invention provides a new nerve-derived transglutaminase enzyme that converts immune-derived IL-2 to dimeric IL-2 having oligodendrocyte cytotoxic activity. Both the nerve-derived transglutaminase and the dimeric mammalian, e.g. human, IL-2, are for use as active ingredients in pharmaceutical compositions for inducing and facilitating regeneration of injured nerves of the central nervous system in mammals.

Growing community of inventors

Tel Aviv, Israel

Shoshana Eitan